News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Abstracts on Allos Therapeutics` RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting


Posted on: 05/28/2004

Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting

Press Release Source: Allos Therapeutics, Inc.

Friday May 28, 8:00 am ET
Data Also to Be Presented on PDX

WESTMINSTER, Colo., May 28 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH - News) today announced that data from poster sessions and abstracts on RSR13 (efaproxiral), the company's investigational radiation sensitizer and PDX (pralatrexate), an injectable small molecule chemotherapeutic agent will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from June 5th to June 8th in New Orleans, Louisiana. Allos Therapeutics, Inc. will host booth #927 at the meeting.
The presentations are scheduled as follows:

RSR13 (efaproxiral)
* Standard Whole Brain Radiation Therapy (WBRT) with supplemental oxygen (O2) with or without RSR13 (efaproxiral) in patients with brain metastases originating from NSCLC: Results of a subgroup analysis. Poster Presentation. Saturday June 5, 2004, 8:00 a.m. - 12:00 p.m. (Abstract #7115; Poster U3)
Presenter: Abdenour Nabid, MD, Centre Hospitalier Universitarie de Sherbrooke, Sherbrooke, PQ, Canada

* Standard Whole Brain Radiation Therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral) in patients with brain metastases: Results of the randomized REACH (RT-009) study. Poster Presentation. Saturday, June 5, 2004, 1:00 - 5:00 p.m. (Abstract #1534; Poster 25)
Presenter: John H. Suh, M.D., Clinical Director, Radiation Oncology, Brain Tumor Institute at the Cleveland Clinic Foundation

* Evaluation of safety and tolerance of escalating doses of RSR13 (efaproxiral) administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial. Poster Presentation. Saturday, June 5, 2004, 1:00 - 5:00 p.m. (Abstract #1533; Poster 24)
Presenter: Pamela Z. New, DO, Assistant Professor, Department of Neurosurgery, Baylor College of Medicine, Houston, Texas

* Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009). Poster Presentation. Sunday, June 6, 2004, 1:00 p.m. - 5:00 p.m. (Abstract #1561; Poster C5)
Presenter: Edward G. Shaw, MD, Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

* Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy. (Abstract No: 3090 -- no presentation or poster session)
Author: Baldassare Stea, M.D., Ph.D. Head of the Department of Radiation Oncology, Arizona Health Sciences Center in Tuscon, AZ, et al.

PDX (pralatrexate)
* A novel antifolate 10-propargyl-10-deazaaminopterin (PDX) displays synergistic effects with gemcitabine in non-Hodgkin's lymphoma models in vitro and in vivo. Poster Presentation. Sunday, June 6, 2004, 8:00 a.m. - 12:00 p.m. (Abstract No: 6596; Poster K7)
Presenter: Radovan Vrhovac, MD, PhD., Memorial Sloan Kettering Hospital

All abstracts may be accessed online at www.asco.org at the conclusion of the meeting. The poster presentations will not be web cast.

About ASCO
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different cancers that strike millions of people around the world every year.

About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy.

Allos recently launched a multi-center Phase 3 randomized open label trial of RSR13 (efaproxiral) as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer. The trial, called ENRICH (ENhancing Whole Brain Radiation Therapy In Patients with Breast Cancer and Hypoxic Brain Metastases), will seek to enroll approximately 360 patients at up to 50 cancer centers across North America.

In addition, Allos is developing PDX, an injectable small molecule chemotherapeutic agent that has an enhanced potency and toxicity profile relative to methotrexate and other dihydrofolate reductase, or DHFR, inhibitors. For more information, please visit the company's web site at: www.allos.com.

-------------------------------------------------------------------------------- Source: Allos Therapeutics, Inc.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740